Industry experts, senior bankers, fintech leaders, entrepreneurs, innovators, investors, and financial institutions from around the globe, are invited to attend the FinovateSpring conference being held on May 21-22, 2024, in Marriott Marquis San Francisco, San Francisco, CA. The important event is gearing up for its 2024 edition and promises an unmatched showcase of advanced fintech technology and networking opportunities. The two-day event will serve as a catalyst for collaboration, key contacts, and advanced fintech solutions.

Businesses today need to embrace the latest technologies and stay ahead of competitors for improved growth and customer experience. FinovateSpring is the West Coast’s leading fintech event that provides an exclusive platform for established businesses and startups to showcase their innovative products, services, and solutions. Featuring live demos and presentations, the event offers attendees a firsthand look at state-of-the-art fintech solutions.

Bigger and Better Fintech Evolution

The 2024 edition of FinovateSpring will feature a prominent lineup of visionaries set to take the stage and share important insights into the latest trends and challenges facing the fintech industry. The event provides attendees with a great opportunity to connect with potential partners, investors, and customers. Attendees can get expert advice across a wide range of categories, including digital banking, lending, wealth management, payments, insurtech, regtech, and more.

FinovateSpring is a community of like-minded professionals who are committed to driving innovation and collaborating on fintech solutions. Attendees can leverage specialized workshops focused on practical strategies for navigating the fintech landscape. Representative speakers for the event include J.P. Morgan, Cornerstone Advisers, Charles Schwab, U.S. Bank, BNY Mellon, HSBC, University of California, Women in Payments, Wells Fargo, Cota Capital & more.

To learn more, please visit https://ibn.fm/cMczz

• TMET.V has 100% ownership in three highway-accessible gold and copper projects that remain largely untested by drilling, covering 1,000 square kilometers within prolific mining districts of Ontario and British Columbia
• Exploration projects include the Filion Gold Project with significant gold potential evidenced by historical sampling, the Kolos Copper-Gold Project showing high-grade values in surface sampling coincident with anomalous geophysics extending 1.5 kilometers into the sub-surface, and the Latham Copper-Gold Project featuring multiple promising anomalies and high-grade rock grab samples in addition to a historical copper-gold porphyry deposit
• Favorable market conditions driven by renewable energy and electric vehicle industries have led to increased copper demand, prices recently reached $10,000/ton

Torr Metals (TSX.V: TMET), a Canada-based mineral exploration company advancing mineral properties in Ontario and British Columbia, Canada. With 100% owned gold and copper projects spanning 1,000 square kilometers, the company aims to unlock the potential of its properties with a focus on cost-effective exploration and development aided by proximity to existing major infrastructure.

TMET’s exploratory activities sync with favorable market conditions driven by the burgeoning renewable energy and electric vehicle industries. Limited copper supply is leading to increased demand by these sectors with a corresponding price increase to nearly $10,000 per ton (https://ibn.fm/hDubI). As a result, investors anticipate a bullish outlook for copper over the next few months driven by rising demand and tightening market conditions.

TMET aims to capitalize on the rising demand for these precious metals by advancing three key exploration projects in its portfolio. The Filion Gold Project, located in Ontario, spans 261 square kilometers, holding significant exploration potential with six unexplored gold targets along the Filion Fault – a known gold host. Historical sampling has confirmed the project’s high-grade gold potential, with rock grab samples reaching up to 9.1 g/t Au and channel sampling hitting 91.4 g/t Au over 0.3m. Recent soil sampling further highlights the company’s positive outlook, with assays hitting up to 1.32 g/t Au within a significant untested soil anomaly measuring 1200 meters in strike-length.

TMET’s Kolos Copper-Gold Project covers 140 square kilometers in British Columbia. The company aims to explore the area’s untapped copper porphyry potential, with recent surface geochemical and sub-surface geophysical results drawing comparisons to regional deposits including the Highland Valley and Copper Mountain Mines(*). Historical rock grab samples have shown high-grade values, with assays up to 4.24 g/t Au, 0.52% Cu, and 11.3 g/t Ag. Recent results published in March and April 2024 indicate 5 significant kilometer-scale copper soil anomalies with coincident geophysics suggesting mineralization could extend up to 1.5 kilometers depth. None of these exploration targets have ever been drilled, providing multiple potentials for a major new copper discovery.

Rounding out the company’s portfolio is the Latham Copper-Gold Project spanning 689 square kilometers in renowned Golden Triangle of British Columbia. Exploration targets include five never-drilled copper-gold soil anomalies defined in 2022 and 2023, as well as the Gnat Pass copper-gold porphyry deposit where historical drilling yielded significant intercepts including 0.64% Cu over 73 meters within broader mineralization extending from surface to over 200 meters vertical depth where it remains open. High-grade rock grab samples from outcrop have also shown recent promising results at-surface on the Dalvenie target, with values reaching up to 14.15 g/t Au, 4.31% Cu, and 63.1 g/t Ag.

TMET’s executive team brings decades of experience in exploration and project development across the Americas. With a portfolio of promising projects in strategic locations, the company is strongly positioned to leverage the surging demand for strategic minerals required by the growing electric vehicle and renewable energy industries.

(*)Comparisons are not necessarily indicative of mineralization on the Kolos Project.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• SenesTech, a rodent fertility control company, through its ContraPest(R) and patent-pending Evolve(TM) soft bait lines, is offering an effective, humane, and safe approach to controlling rat populations, and the diseases rodents can bring with them
• The company’s growing success speaks to the superiority of the company’s offerings, along with the overall effectiveness of its products

SenesTech (NASDAQ: SNES), the inventor of the only EPA-registered contraceptive for male and female rats, recognizes the risks associated with growing rodent populations, especially in cities and areas with a substantial human population. Following its years of experience in the field, the company understands the value of a humane and hygienic approach to controlling rat populations, with non-poison approaches that don’t threaten other animals. This has driven the development of its unique and effective products, and has given it a major competitive edge over its peers in the sector, promoting the company’s rapid and continuing sales increase.

With its fertility control products, SenesTech offers a proven way for entire cities and urban areas to reduce rat populations by over 90%. Available in a variety of delivery systems, SenesTech’s products allow for easy and efficient product deployment, an approach that is achieving significant acceptance in the market (https://ibn.fm/W25DI).

SenesTech’s approach is much needed throughout the industrialized and agricultural world, particularly factoring in how rodents can directly transmit a range of pathogens and disease. They have been known to cause human diseases such as hantavirus, rat bite fever, salmonellosis, and leptospirosis. In addition, these rodents have been known to host pests such as fleas and ticks, which transmit other diseases including, but not limited to, plague, tularemia, Lyme disease, and tickborne relapsing fever (https://ibn.fm/9wDor).

The situation is made worse, given how fast rodents can reproduce. Despite having an average lifespan of 9-12 months, many mice and rat species sexually mature as early as 4-5 weeks of age and have a gestation period of only 21 days. With the right environment, which entails adequate food and warm habitat, rats can have six litters a year, consisting of up to 18 pups each (https://ibn.fm/bw4sV). As such, unless addressed as early as possible, these populations can get out of hand quickly and wreak havoc, both from an environmental and a health perspective.

To address this, SenesTech has been advocating non-lethal rodent birth control products added to or separate from existing integrated pest management plans. Their products can be used separately, or in conjunction with additional rodent control methods.

“The most [effective approach] is combining the elements of integrated pest management and having them work together and support each other,” noted Joel Fruendt, SenesTech’s CEO. (https://ibn.fm/UDul0).

SenesTech’s management is optimistic that as time progresses, more people will learn of the value of its offerings and adopt its solutions. According to them, it speaks of the superiority of its solutions, the company’s market positioning, and the overall value it delivers to its customers.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Tartisan originally released a Preliminary Economic Assessment (“PEA”) report in 2022, which confirmed the significant nickel-copper-cobalt mineral resource at its 100%-owned Kenbridge Nickel Project
• The PEA noted that the measured and indicated mineral resources represent 3,508,000 tons at 0.70% Ni, 0.35% Cu, and 0.01% Co (54 Mlb Ni, 27 Mlb Cu), while inferred mineral resources represent 1,013,000 tones at 1.21% Ni, 0.56% Cu, and 0.01% Co (27 Mlb Ni, 13 Mlb Cu)
• The PEA also indicated a 9-year mine plan based on a 1,500-ton-per-day underground mining and processing operation
• The company transitioned to the Advanced Exploration (“AEX”) and Project Development Phase following the release of the PEA
• The Advanced Exploration and Project Development Phase is designed to expand the company’s understanding of the Kenbridge Deposit and enhance the current resource

Located in the Kenora Mining Division in northwestern Ontario, the Kenbridge Nickel Project is the flagship project of Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral exploration and mining development company. The project has an existing shaft to a depth of 622 m (2,042 ft), with level stations at 45 m (150 ft.) intervals below the shaft collar and two levels developed at 107 m (350 ft) and 152 m (500 ft) below the shaft collar. Accessible by gravel roads from paved Highway 71, it is covered by patented and unpatented mining claims totaling 4,108.42 ha and registered to wholly owned subsidiaries of Tartisan Nickel.

Historical exploration and project development of the Kenbridge Nickel Project took place between 1936 and 2008. And during this period, five main companies completed mineral prospecting, geological mapping, geophysical surveys, trenching, and drilling programs.

Tartisan nonetheless acquired 100% of the Kenbridge Property from Canadian Arrow in 2018 and embarked on refurbishing the access road into the site and reestablishing the cut-line grid. The company then completed an ASTER LWIR imagery study in 2020, followed by a surface time domain electromagnetics survey and a borehole electromagnetic survey in the spring of 2021. Later in 2021, the company commenced drilling, the first drilling program since 2008.

The company completed ten drill holes totaling 8,988 m on the Kenbridge Nickel Project and four additional drill holes totaling 2,419 m on the Kenbridge North target as part of the 2021 drilling program. These drill holes brought the total number of drill holes completed on the property to 665, all totaling a drilling length of 99,741 m, according to the Preliminary Economic Assessment (“PEA”) report independently prepared by P&E Mining Consultants Inc. (https://ibn.fm/549xs).

Drilling and assay data provided by Tartisan and compiled, verified, and validated by P&E were used to create an updated MRE, which confirmed that the Kenbridge Project “contains a significant nickel-copper-cobalt mineral resource that is potentially amenable to underground mining.” The PEA noted that the measured and indicated mineral resources represent 3,508,000 tons at 0.70% Ni, 0.35% Cu, and 0.01% Co (54 Mlb Ni, 27 Mlb Cu), while inferred mineral resources represent 1,013,000 tones at 1.21% Ni, 0.56% Cu, and 0.01% Co (27 Mlb Ni, 13 Mlb Cu) (https://ibn.fm/szYAB).

Additionally, the PEA indicated a 9-year mine plan based on a 1,500-ton-per-day underground mining and processing operation. This mine plan assumes the potentially extractable tonnage of measured, indicated, and inferred mineral resources, which, in turn, assumes an overall dilution of 47% and a 94% mine recovery factor. The PEA also estimated the life of mine (“LOM”) revenues, basing its calculations on the long-term industry consensus forecast for metal prices. It also estimated the LOM operating costs, mining costs, LOM capital costs, pre-tax net present value (“NPV”), pre-tax internal rate of return (“IRR”), net cash flow, and after-tax NPV, after-tax cash flow, and after-tax IRR.

Expressing his satisfaction with the results of the PEA, which is focused solely on the current underground mineral resource, Mark Appleby, President and CEO of Tartisan, said, “There remains excellent potential to increase and upgrade the quality of the near-surface mineralization at Kenbridge thereby adding additional years of production or providing the basis for an increase in annual throughput.”

However, Appleby explained that the company would initially focus on underground mining, saying, “By adjusting the mining plan to be an underground operation, it allows Tartisan to utilize the existing shaft infrastructure, thereby accessing higher grades of mineralization early in the proposed mine life. The PEA provides compelling evidence to move toward feasibility and for the Kenbridge Nickel Project to move into production.”

Following the release of the PEA in 2022, Tartisan transitioned to the Advanced Exploration (“AEX”) and Project Development Phase, retaining Nordmin Engineering Ltd., a consulting engineering firm, to assist in developing a plan for this phase, according to a March 2023 news release (https://ibn.fm/zovIo). The company’s management believes that the AEX will expand the company’s understanding of the Kenbridge Deposit and enhance the current resource. Recently, Tartisan hired Northwest Solutions Inc. to provide road design, permitting, and project management support to the Kenbridge Nickel Project (https://ibn.fm/rK6C6).

For more information, visit the company’s website at www.TartisanNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to TTSRF are available in the company’s newsroom at https://ibn.fm/TTSRF

BizCann invites traders, vendors, entrepreneurs, regulatory authorities, investors, and cannabis enthusiasts, to attend the BizCann Expo being held in Medellin, Colombia, May 18-19, 2024. The BizCann Expo is organized by ZJ Events, bringing the businesses and professionals of the cannabis industry and its ancillaries to a common forum for networking, trading, and learning sessions.

Having spread its reach over several cities in the US, BizCann Expo is being held in Medellin, Colombia, this year to offer phenomenal trading opportunities to local businesses. Due to its favorable location, connectivity, and rich history, Medellin offers the perfect venue for hosting this networking event.

In the year 2023, the event witnessed 50+ speakers, 200+ vendors, and 5,000+ attendees who connected over two days of networking and learning at the BizCann Expo. This year the participation is expected to outgrow last year’s numbers. Industry professionals with fresh and unique ideas can leverage this expo forum to gain visibility among peers, industry giants, and investors.

Entrepreneurs and creative minds with unique business ideas can share their innovations on this platform. Several eminent industry leaders will attend the expo to discuss the latest updates and strategies for successful canna trading. Plant-touching and non-plant touching cannabis businesses will also be represented at the Expo.

The speaker sessions will be conducted by stalwarts of the cannabis industry who have years of knowledge and experience of trading in this industry. They will discuss the latest updates, regulations, challenges, and prospects that lay ahead for businesses to grow and prosper. (Applications for speaker sessions are open.)

To learn more, please visit https://ibn.fm/HqJFj

The ZJ Events Vape South America 2024 will be held at the Plaza Mayor Convention Center, Medellin Colombia, May 18-19, 2024. Top manufacturers, buyers, suppliers, users, traders, enthusiasts, and stalwarts of the alternative products industry will be attending the always popular event.

The counterculture and vape trade show will showcase a myriad of alternative products that include herbal products, mood enhancers, vape products, functional beverages, dietary supplements, nootropics, and more.

Suppliers, traders, head shops, and several businesses from the alternative category, will be part of the Expo, to showcase their latest products and services. Attendees can leverage huge discounts, get amazing deals, and explore the most innovative products, all under the fun and exciting environment of the expo.

As traditional and mainstream marketing is difficult for alternative products, an exclusive channel must be available to market and showcase the alternative products. ZJ Events offers the counterculture industry a robust platform with their Alternative Products Expo, where the best of the industry influencers meet, connect, and collaborate.

The event offers:

• Registered buyers and brands, with media and marketing partnerships
• Mass exposure to new players, industries, and innovations in the counterculture realm
• Investors and traders, for discovering new products and trends
• Networking with industry veterans and distributors for network expansion and a better ROI
• Updates on the latest industry regulations

Vape South America started as Vape Conventions in 2017, evolved into USA CBDEXPO, and has been known as Alternative Products Expo in the United States since 2021. Dedicated booths are available for traders and innovators where they can showcase their innovative ideas and brands. Businesses can opt for different categories of sponsorships like platinum, gold, silver, etc., for extensive marketing by the event organizers.

To learn more, please visit https://ibn.fm/U1EwR

In an era where convenience and efficiency stand as pillars of service delivery, HealthLynked (OTCQB: HLYK) has introduced an innovative online patient booking system, akin to how OpenTable simplifies restaurant reservations. This seamless integration of technology and healthcare is transforming how patients interact with medical services, ensuring that setting up a doctor’s appointment is as easy as booking a dinner date.

The Booking Process: Tailored for Simplicity and Flexibility

HealthLynked’s online booking system is designed with the user experience at the forefront. The process is straightforward: patients select their preferred doctor, date, and whether they prefer a morning or afternoon appointment. This flexibility not only enhances convenience but also allows healthcare providers to manage their schedules efficiently, accommodating more patients while delivering personalized care.

Here’s How It Works:

1. Selection of Doctor and Timing: Patients can browse and select from a Directory of doctors based on specialty, availability, and ratings. Choosing a general time of day (morning or afternoon) provides the system and the healthcare provider flexibility in scheduling, which is particularly beneficial for managing daily patient volumes.
2. Reason for Visit: Patients specify the reason for their appointment, enabling the doctor to prepare in advance and tailor the consultation to the patient’s needs.
3. Personal Information: To book the appointment, patients need to provide basic information including their first and last name, date of birth, address, phone number, and email address.
4. Account Creation and Recognition: If a patient has not previously created an account, one is automatically set up upon their first booking. This account simplifies future interactions with the system by remembering user details, reducing the need to re-enter information. Returning patients can simply enter their email or phone number, and the system prompts them for their password.

First-Time and Returning Users: An Inclusive System

HealthLynked extends the convenience of this system to both new and returning patients. First-time users have the privilege of booking with any doctor across the country, broadening their options and access to healthcare. For returning patients, especially those who are free members, there is an encouragement to upgrade to a paid membership should they choose to book with an out-of-network doctor. This membership, priced at $12 per month or $10 per month when paid annually, ensures patients can consistently receive care from their preferred healthcare providers.

Why HealthLynked’s System Stands Out

This model resembles OpenTable’s approach to restaurant bookings, where ease and accessibility are paramount. HealthLynked leverages similar principles to enhance healthcare accessibility and patient satisfaction. The system not only prioritizes user convenience but also integrates advanced features that remember user preferences and streamline the booking process.

Conclusion: A Step Towards More Connected and Accessible Healthcare

By integrating a user-friendly online booking system, HealthLynked is setting a new standard in healthcare delivery. This innovation not only makes medical consultations as easy as booking a table at your favorite restaurant but also significantly improves the efficiency of healthcare services. As HealthLynked continues to refine and expand its offerings, the potential to further enhance patient engagement and satisfaction seems boundless. With such technologies, the future of healthcare is not only interconnected but also intuitively aligned with the needs and expectations of modern patients.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Third-Party Content

The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/

• SuperCom Ltd. is focused on developing its portfolio of products in support of advanced electronic monitoring (“EM”) solutions, and reported last month record-level revenues and EBITDA during the past year
• SuperCom’s recent positive financials report represents the results of the company’s efforts to introduce non-incarceration EM alternatives around the world, with inroads in Europe and the U.S. resulting in significant contracts
• Electronic technology for tracking criminal offenders and other court-administered programs provides a more economical approach to security than incarceration in cases where such options applicable

Electronic-monitoring (“EM”) security solutions developer SuperCom (NASDAQ: SPCB) has seen its revenues and gross margin grow dramatically as it serves a worldwide market for court-administered security needs and other identity technology concerns.

The technology solutions company reported its Q4 and fiscal year-end financial results April 22, noting a 51 percent jump in annual revenue (its third consecutive year of growth), a 60 percent increase in gross profits for the year and a remarkable 2,350 percent burst in its EBITDA (https://ibn.fm/ZiTb4).

The figures include a quarterly increase in the company’s gross margin to 41.4 percent. SuperCom presented the record-level results to investors in a conference call and Q&A on April 22.

“These financial metrics not only underline our strong execution, but also the increasing efficiency and scalability of our operations. During the past year, we won several award contracts in the U.S. and Europe, and we’re excited about the opportunity we see ahead,” CEO and President Ordan Trabelsi said as he introduced the conference call (https://ibn.fm/o9QOH). “Since 2018, SuperCom has secured over 50 new multi-year government projects. Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win.”

SuperCom is focused on developing IoT tracking opportunities using its suite of technological products, including PureProtect for domestic violence monitoring, the comprehensive PureOne GPS tracking solution and the PureSecurity platform that is being upgraded with advanced AI integration.

Along with that focus, the company also launched a new project in Iceland that involved upgrades to a system supporting the secured issuance of national ID cards and passports that had previously been deployed.

“This growth is a testament to our competitive edge and ability to secure significant contracts, such as the $33 million national domestic violence project and other multiple high-value projects in Europe and California, reflecting our commitment to excellence and our ability to meet the diverse needs of our international clientele,” Ordan said.

The PureProtect product is particularly important as a solution with life-saving potential. It provides improved protection to families suffering from domestic violence. It was a new rollout during the past year along with PureOne, which delivers a competitive all-in-one GPS tracking ankle bracelet monitoring solution tailored to the North American market.

Ordan said that high recidivism rates and the increasing costs associated with incarceration are making SuperCom’s electronic monitoring solutions an attractive alternative for governments that want to cut their costs while ensuring public safety.

During the past years, SuperCom sealed significant new contracts in a competitive bidding process, allowing the company to expand into 10 new countries in the European market, he reported.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Fast anneal is expected to impact various quantum computing applications, from advanced scientific research in quantum simulation to AI and solving real-world problems across wide spectrum of industries
• It expands upon D-Wave’s groundbreaking optimization achievements, utilizing the comprehensive coherent annealing quantum computing provided by D-Wave’s Advantage(TM) systems and the cutting-edge Advantage2(TM) prototype
• The introduction of the fast-anneal feature is poised to attract both commercial and academic researchers aiming to develop top-tier applications, broaden benchmarking investigations, and correlate heightened coherence with enhanced performance

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the launch of the fast-anneal feature, which is available on all D-Wave’s quantum processing units (“QPUs”) in the D-Wave Leap real-time quantum cloud service. Fast anneal is expected to impact a number of quantum computing applications, most notably advanced scientific research.

D-Wave’s fast-anneal feature has been a key part of the company’s research milestones, including published work in Nature Physics (2022) and Nature (2023), demonstrating the advantages of annealing quantum computing over classical algorithms for solving complex optimization problems. Now that this functionality is readily available, customers can conduct quantum computations at remarkable speeds, effectively mitigating the influence of external interferences like temperature changes and background noise, which typically impede quantum calculations.

By providing enhanced control for significantly quicker annealing durations compared to previous options, this feature sets the stage for customers to replicate and expand upon D-Wave’s groundbreaking optimization achievements utilizing the comprehensive coherent annealing quantum computing provided by D-Wave’s Advantage systems and the cutting-edge Advantage2 prototype, the most performant system the company has developed thus far.

“Providing direct access to Fast Anneal, which has been at the heart of D-Wave’s recent advancements, represents a significant step forward in our mission to provide customers with the resources they need to drive innovation and achieve extraordinary results,” said Dr. Alan Baratz, CEO of D-Wave (https://ibn.fm/WgOEf). “We believe it will further empower them to build industry-shaping applications with the most powerful quantum computing environment available today.”

Customer interest in D-Wave’s cutting-edge annealing quantum computing technology is evident through the utilization of its two Advantage2 experimental prototypes, which collectively have addressed almost eight million customer inquiries since their introduction in 2022 and 2024. The new fast-anneal feature is poised to attract both commercial and academic researchers aiming to develop top-tier applications, broaden benchmarking investigations, and correlate heightened coherence with enhanced performance.

Ed Heinbockel, president and CEO of SavantX, a D-Wave customer, welcomed the new functionality, saying that by providing direct access to quantum computing’s central nervous system, D-Wave is single-handedly opening new horizons for research on quantum computing and AI. “We believe the new capability will help us realize significant benefits of coherence on application development that we’d otherwise be unable to achieve,” he added.

The announcement was also praised by Christopher Savoie, co-founder and CEO of Zapata AI, who underlined that the ability to use the fast-anneal feature to directly interact with D-Wave’s Advantage2 prototype is exciting for Zapata AI’s work building quantum-enhanced generative AI models trained on molecular data to accelerate drug discovery and design new materials. “The fast-anneal feature can produce coherent distributions that have the potential to allow more efficient encoding of complex data patterns in a way that is classically impractical,” Savoie added. “In addition to molecular discovery applications, this feature could also be valuable in other industrial applications involving complex data patterns, particularly in combinatorial optimization problems found across industries.”

D-Wave’s customers include over two dozen Forbes Global 2000 companies and blue-chip industry leaders like Mastercard, Deloitte, Unisys, NEC Corporation, DENSO, and more. Their client success stories can be found on the company’s website (https://ibn.fm/aDOwo).

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of its Quarterly Reports on Form 10-Q and in the company’s other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

• PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin
• The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024
• PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions
• The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101, an IV formulation of suramin. This accomplishment marks a significant step toward submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the fourth quarter of 2024 (https://ibn.fm/52o4M).

This step paves the way for potential commercial availability in the U.S. of Suramin, the sole form for treating Stage 1 Human African Trypanosomiasis (“HAT”) caused by Trypanosoma brucei rhodesiense. This disease, fatal and neglected, represents a critical healthcare challenge. Pending FDA approval, this milestone is crucial for PaxMedica as it seeks FDA approval for PAX-101, pending a thorough review process., which is recognized as the standard treatment for HAT outside the United States, according to the CDC.

A favorable review and NDA approval may also position the company to receive a Tropical Disease Priority Review Voucher (“PRV”). PaxMedica aims to establish a sustainable global supply chain for PAX-101, primarily as a step financially enabling the company to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”).

ASD comes with different challenges, and PaxMedica’s robust pipeline of products may help reduce, or modulate some of the more troublesome aspects of ASD. This advancement would allow people with autism to integrate their behavior with others more successfully and improve their lives.

According to Fortune Business Insights, the ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030, expanding at a CAGR of 8.5% during the forecast period. The growing prevalence of ASD and increasing access to treatment options are encouraging more ASD patients and their families to seek treatment regimens (https://ibn.fm/aavzi).

Howard Weisman, chairperson and CEO of PaxMedica, commented on the recent developments, stating, “This completion of our registration/validation batches is a crucial step as we prepare for an NDA submission for PAX-101. It marks a significant milestone in our ongoing efforts.” He further elaborated, “Our long-term vision includes extending our clinical investigations of PAX-101 as a potential treatment for individuals with Autism Spectrum Disorder. This manufacturing achievement has significantly aided in overcoming one of the major barriers to initiating further tests on PAX-101 for addressing the core symptoms of ASD, which remain under investigation.”

“The progress we’ve made brings us closer to our objective of becoming a reliable global supplier of suramin, particularly for treating Stage 1 Human African Trypanosomiasis (‘HAT’), a condition for which suramin is recognized as one of the World’s Essential Medicines,” Weisman added. “It is our aim to eventually undertake clinical trials to explore the use of PAX-101 for the core symptoms of ASD. It is important to note that there are currently no approved medications that address these symptoms directly, making our research both challenging and essential.”

PaxMedica is on a promising path to change the future of ASD, bringing hope to millions. The company hopes to add this important new treatment option to improve the prospect of independence. It has the potential to help adolescents and young adults lead brighter, more independent lives.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD